Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Citric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 4/20 | 0.84 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.30 |
| ▸ | FAHD1 | Q6P587 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citric Acid SCHEMBL379041 | 1.00 | CA4 (0.84) | CA4ALDH1A1CASP1FAHD1 | |
| Citric Acid SCHEMBL1303277 | 0.97 | CA4 (0.90) | CA4ALDH1A1CASP1FAHD1 | |
| Citric Acid SCHEMBL7004500 | 0.97 | CA4 (0.89) | CA4ALDH1A1CASP1FAHD1 | |
| Citric Acid SCHEMBL47867 | 0.97 | CA4 (0.89) | CA4ALDH1A1CASP1FAHD1 | |
| Citric Acid SCHEMBL445486 | 0.97 | CA4 (0.89) | CA4ALDH1A1CASP1 | |
| Citric Acid SCHEMBL2974121 | 0.97 | CA4 (0.89) | CA4ALDH1A1CASP1FAHD1 | |
| Citric Acid SCHEMBL906010 | 0.97 | CA4 (0.89) | CA4ALDH1A1CASP1FAHD1 | |
| Citric Acid SCHEMBL5471628 | 0.97 | CA4 (0.89) | CA4ALDH1A1CASP1 | |
| Citric Acid SCHEMBL22124526 | 0.95 | CA4 (0.85) | CA4CASP1FAHD1 | |
| Citric Acid SCHEMBL378980 | 0.94 | CA4 (0.84) | CA4ALDH1A1CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 991 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122017257-A | Detection method and detection kit for oxidized low-density lipoprotein | 济南玖方生物科技有限公司 | 2026-05-12 | — | — | CN | claimed |
| US-20260060973-A1 | Ophthalmic Composition for Treating Non-Infectious Inflammatory Diseases | VIVAVISION BIOTECH LTD (CN) | 2026-03-05 | — | — | US | claimed |
| EP-4702973-A1 | OPHTHALMIC COMPOSITION FOR TREATING NON-INFECTIOUS INFLAMMATORY DISEASES | Vivavision Biotech Ltd. (CN) | 2026-03-04 | — | — | EP | claimed |
| EP-4702974-A1 | OPHTHALMIC COMPOSITION CONTAINING VVN001 | Vivavision Biotech Ltd. (CN) | 2026-03-04 | — | — | EP | claimed |
| US-12324871-B2 | Absorbable iron-based alloy implanted medical device and manufacturing method thereof | BIOTYX MEDICAL (SHENZHEN) CO., LTD. (CN) | 2025-06-10 | — | — | US | claimed |
| CN-119581238-A | Lignin-based porous carbon for super capacitor and preparation method thereof | 江南大学 | 2025-03-07 | — | — | CN | claimed |
| CN-114566723-B | Electrolyte for rechargeable electrochemical cells | EOS能源技术控股有限责任公司 | 2025-03-04 | — | — | CN | claimed |
| CN-116219439-B | Etchant, preparation method and application thereof | 上海盛剑微电子有限公司 | 2025-02-11 | — | — | CN | claimed |
| CN-113796519-B | Method for preparing water-in-oil-in-water type multiple emulsion | 财团法人食品工业发展研究所 | 2025-01-14 | — | — | CN | claimed |
| CN-119243309-A | PVD electrolytic stripping agent for surface of titanium anode film stainless steel composite material and stripping method thereof | 广州市巴斯富环保材料有限公司 | 2025-01-03 | — | — | CN | claimed |
| US-5897877-A | PELLETS COATED WITH A POLYMER RESISTANT TO THE STOMACH'S GASTRIC JUICE, AND CONTAINING AN ACID SALT, SUCH AS POTASSIUM DIHYDROGEN PHOSPHATE, A SEPARATING AGENT, AND A SOFTENING AGENT; QUICK RELEASE INTO INTESTINAL TRACT | SPIRIG AG, PHARMAZEUTISCHE PRAEPARATE (CH) | 1999-04-27 | — | — | US | claimed |
| EP-0831706-A1 | METHOD OF STABILIZING BIOCIDAL COMPOSITIONS OF HALOALKYNYL COMPOUNDS | TROY CHEMICAL CORPORATION (US) | 1998-04-01 | — | — | EP | claimed |
| US-5653917-A | Rust-removing alkali metal hydrogen citrate composition | SINGERMAN GARY M (US) | 1997-08-05 | — | — | US | claimed |
| EP-0233110-B2 | Use of a salt to influence the flow characteristics of thickened compositions | RHONE POULENC CHIMIE (FR) | 1997-03-19 | — | — | EP | claimed |
| WO-1996039836-A1 | METHOD OF STABILIZING BIOCIDAL COMPOSITIONS OF HALOALKYNYL COMPOUNDS | TROY CHEMICAL COMPANY (US) | 1996-12-19 | — | — | WO | claimed |
| US-4961927-A | Clear solution containing lysozyme hydrochloride and dipotassium glycyrrhizinate | EISAI CO., LTD. (JP) | 1990-10-09 | — | — | US | claimed |
| US-4824664-A | ANTIHISTAMINES | LABORATOIRES SMITH KLINE & FRENCH (FR) | 1989-04-25 | — | — | US | claimed |
| US-4346709-A | Drug delivery devices comprising erodible polymer and erosion rate modifier | ALZA CORPORATION (US) | 1982-08-31 | — | — | US | claimed |
| US-4200586-A | Inhibiting the carbon-carbon double bond isomerization of substituted or unsubstituted hydrocarbon compounds | PHILLIPS PETROLEUM COMPANY (US) | 1980-04-29 | — | — | US | claimed |
| US-4104190-A | Generation of chlorine dioxide for disinfection and sterilization | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1978-08-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260060973-A1 | Ophthalmic Composition for Treating Non-Infectious Inflammatory Diseases | JAK1, TYK2, JAK3 | CA4 3086/4885ALDH1A1 2996/4885CASP1 877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.